Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Pneumococcal Vaccination in Aging HIV Positive Individuals
NCT03039491Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2015
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Prevnar 13 in Pneumococcal pneumonia (PP) (8 arms), sponsored by Medical University of South Carolina. Primary endpoints: Antibody response at Day 30 and Opsonophagocytic antibody activity at Day 30. Started Sep 2015; status: completed.
02
Drugs
Prevnar 13
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT03039491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039491.